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Objectives: Instanyl® (fentanyl nasal spray) received European market authorisa-
tion in July 2009 for the management of breakthrough pain in adults already receiv-
ing maintenance opioid therapy for chronic cancer pain, with precise instructions 
on indications for use and dosage. The study objectives were to evaluate patient-
reported misuse, abuse, and diversion of Instanyl® in real-life in France. MethOds: 
Cross-sectional observational study of patients with an Instanyl® dispensation from 
a non-hospital pharmacy. An anonymous self-administered questionnaire was dis-
tributed to patients at the time of drug dispensation between 27 July 2011 and 12 
November 2012. The questionnaire collected data on indication, contraindications, 
Instanyl® use, and previous completion of the questionnaire. Results: Among the 
272 eligible questionnaires (at least one item completed in addition to age, gender, 
time since first prescription, and absence of previous completion of the question-
naire), all patients were adult and 95% declared misuse. Among the 160 patients 
who declared having cancer, 94% declared misuse: 76% declared at least one indica-
tion/contraindication misuse and 86% at least one posology misuse. Widening the 
definition of use for breakthrough pain to use for both breakthrough and chronic 
pain in cancer patients, reduced the indication/contraindication misuse (63%), but 
when posology misuse was also considered this did not markedly change overall 
misuse (93%). Abuse of Instanyl® (using the drug for emotional reasons, relaxation, 
or sleep disorders) concerned 21 patients (15 with cancer, and 6 without); diversion 
(passing the drug to another person) concerned 2 patients (1 with cancer and 1 
without). cOnclusiOns: Misuse of Instanyl® was widespread. Nearly half reported 
not to have cancer, and among those who did, only a few used this drug correctly. 
There seems to be a communication deficit as to the proper prescribing of this drug, 
and its proper use when prescribed.
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Objectives: Obtaining feedback from participants in clinical trials using a struc-
tured method is a valuable opportunity to identify strengths and weaknesses of 
trial design and conduct, highlight improvement opportunities and provide patient 
insight to help future recruitment. This study aimed to develop a questionnaire 
to provide a structured approach to evaluate patients’ experience of clinical trial 
participation. MethOds: A draft questionnaire assessing patients’ experiences 
before, during and after the trial was developed in collaboration with oncology 
patient-advocates before being qualitatively reviewed by individuals who have 
participated in a clinical trial or who have provided support to trial participants. 
A literature review informed these draft concepts. Three interviewer-led focus 
groups involving clinical trial participants (on-going or completed within the last 
12 months) (n≤ 9/group) were conducted to evaluate the concepts, and elicit fur-
ther concepts for questionnaire inclusion. An updated questionnaire was devel-
oped based on combined insights from the focus groups and literature review. 
Content validity of the revised measure was considered using cognitive debrief-
ing interviews (n= 12). This testing aimed to identify the relevance and clarity 
of the instrument. Results: A literature review confirmed the relevance of the 
concepts assessed by the draft questionnaire. Aspects of the draft questionnaire 
included the trial enrolment and consent process, logistics of study participa-
tion and dissemination of results. The focus group participants provided further 
evidence on the relevance of the concepts included in the draft instrument and 
the importance of capturing the clinical trial experience from the patient perspec-
tive. Cognitive debriefing results are also presented. cOnclusiOns: The results 
provide evidence to support the content validity of the post-trial questionnaire. 
Assessing the clinical trial experience from the patient perspective using a robust 
questionnaire may offer potential to improve trial design and ensure subjects stay 
engaged throughout the trial process.
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Objectives: Assessing the effects of breast reconstruction (BR) on patient-reported 
outcomes (PRO) is important as BR becomes increasingly common after mastectomy. 
A systematic literature review was conducted to assess the clinical use of a well-
validated PRO instrument, the BREAST-Q (BQ) in women undergoing BR. MethOds: 
Searches using PubMed, ScienceDirect, Cochrane Library, and references in plastic 
surgery journals were conducted from when BQ was developed in 2008 to May 2014 
using the term, ‘breast-q OR breastq’. Non-English, reviews, letters, protocols and 
single-patient case reports were excluded. BQ modules unrelated to reconstruction 
(e.g., Augmentation or Reduction) were also excluded. Each BQ scale score ranged 
from 0-100 with a higher score representing better PRO. Results: After applying 
exclusion criteria, 35 studies were retrieved. Majority of studies were conducted in 
North America (54%, 19/35) or Europe (29%, 10/35). Study sample size ranged from 
N= 14 to 7,110 with mean age ranging 46-55 years. When compared to mastectomy 
alone, BR was associated with higher PROs (p< 0.05) however, adjuvant radiotherapy 
was associated with significantly lower PROs than without radiotherapy (p< 0.05). 
Among PRO scales, sexual well-being was consistently low (range: 30-84) and the 
scores of physical well-being and satisfaction with surgeons were consistently high 
(ranges: 68-89 and ≥ 70, respectively). Majority of the studies administered BQ as 
a single administration post-BR. Only 4 studies reported the change from pre- to 
post-BR (Range of change score = -19 to 36). From 3 of 4 studies, the scale with 
the largest Cohen’s d effect size (ES) was psychosocial well-being (ES range: 1.52-
3.83). cOnclusiOns: Our findings suggest that while BQ is widely used, study 
type and method of administration are disparate. Further assessment of the BQ 
much more accessible and informative, and require less filtering through irrelevant 
posts. For example, posts from breast cancer patients typically discuss side effects of 
investigations and treatments and how to manage them, as well as offering emotional 
support. The limitations of using this type of information include the lack of a mecha-
nism to confirm that contributors really do have the relevant disease, although the 
number of “factitious” patients is likely to be small and outweighed by “true” patients 
and caregivers. cOnclusiOns: This study showed that more valuable information 
can be found in patient-to-patient correspondence in forum threads than in general 
social media. Breast cancer patients appear to be more vocal in patient forums than 
schizophrenia patients, possibly due to the stigma attached to mental health prob-
lems. Little was found on what matters to breast cancer caregivers, since patients 
tend to present their own personal experience.
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Objectives: Limited data are available on the health-related quality of life (HRQOL) 
of patients with metastatic renal cell carcinoma (mRCC) in daily practice. The aim 
of this study was to estimate HRQOL of patients with mRCC in daily practice, and to 
assess the influence of patient- and disease characteristics, such as comorbidities 
and adverse events on HRQOL. MethOds: Patients with mRCC were selected from 
a Dutch population-based registry (PERCEPTION). In this RCC registry, data were col-
lected on patient- and disease characteristics, treatments and adverse events. To 
measure HRQOL, a generic questionnaire (EQ-5D) was used. Multiple linear regres-
sion was used to determine which patient- and disease characteristics were associ-
ated with HRQOL. Results: In this study, 100/465 (21.5%) patients presented with 
or progressed to mRCC. Average age at diagnosis was 62.9 years (range: 40-82) and 
77% was male. Patients with mRCC reported an average EQ-5D utility score of 0.73 
(95%CI: 0.64-0.82) at diagnosis. Two to six months after diagnosis, the average EQ-5D 
utility score was 0.75 (95%CI: 0.66-0.84) (P= 0.319). Multiple linear regression showed 
that presence of comorbidities (> 1), number of metastatic sites (> 1), radiotherapy 
and presence of grade 3 or grade 4 toxicity were significantly associated with a lower 
EQ-5D utility score. Although presence of bone metastases significantly lowered 
the EQ-5D utility score, this factor was not significant after adjustment for other 
factors. cOnclusiOns: This is one of the first studies that provides insights into 
the HRQOL of patients with mRCC in daily practice. In contrast to previous studies, 
this study also identified patient- and disease characteristics that influence HRQOL. 
Presence of comorbidities, number of metastatic sites, radiotherapy and presence of 
severe toxicity related to targeted therapies were significantly associated with HRQOL. 
This information is helpful in correcting EQ-5D utility scores for these characteristics, 
and will be useful in future cost-effectiveness analyses.
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Objectives: Childhood cancer’s profound effects should be assessed appropriately 
within clinical trials: however, a conceptual model is required to help design appropriate 
measurement strategies. The aim of this study was to develop an initial pediatric oncol-
ogy conceptual model. MethOds: Key databases were searched for articles focused on 
qualitative research with children (ages 0-18) with cancer and/or their caregivers. Four 
patient/parent internet forums were reviewed. Telephone interviews with five pediatric 
oncology clinicians were performed. Data were analyzed using grounded theory meth-
ods. Results: 112 qualitative studies were reviewed. Few studies presented data by 
specific cancer type/stage or child age; blogs/clinician interviews provided insights into 
these areas. Across cancer types, but especially for hematological cancers, pain, fatigue, 
and “feeling unwell”/fever were emphasized, as well as impacts on daily function-
ing. For brain tumors, headaches, sudden lack of coordination/balance, blurred vision, 
seizures, vomiting, dizziness and cognition-related impacts on mood and language 
were highlighted. For solid tumors, tumor-location pain often led to related mobility 
and/or functioning problems; clinicians emphasized lymphadenopathy and weight 
loss. Adolescents appeared to be most impacted by cancer, due to their grasp of the 
cancer’s gravity, self-image issues, loss of autonomy, school absences and social life 
limitations. Though patients/parents/clinicians found it difficult to distinguish between 
treatment- and cancer-related symptoms, treatments caused several problems, such 
as neutropenia, changes in appearance, irritability, nausea/vomiting, fatigue and pain. 
Not emphasized by clinicians but reported frequently in literature/blogs, mucositis and 
changes in tastes concerned parents/children. Clinicians strongly emphasized short-
term/long-term/working memory loss and that anxiety contributed to the occurrence/
severity of other side-effects/impacts. cOnclusiOns: Cancer’s impact on children is 
multifaceted and complicated. Issues identified in this review that must be considered 
when designing outcomes strategies are: the child’s age, cancer type and stage, delineat-
ing disease and treatment symptoms/impacts, and short/long term side effects impacts 
on nutrition and development.
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of administration” was less important for participants (coef.: 0.141). cOnclusiOns: 
“Progression-free survival” and “tumor-associated symptoms” were identified as key 
patient-relevant characteristics in this study. The sole consideration of the “progres-
sion-free survival” as foundation for decisions is not sufficient from the patients’ 
perspective and multiple criteria are important. Subgroup analysis revealed that the 
importance of “progression-free survival” increases with increased therapy experi-
ence. Basically, the results give insight into how much a deciding factor affects the 
treatment decision from the perspective of patients. In addition, the results of this 
survey can provide a basis for patient-oriented evaluation of treatment options 
in NSCLC.
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Objectives: This study aimed to (i) investigate the impact of subjective and objective 
factors on colorectal cancer carer physical and mental health, and (ii) identify key 
subjective burden predictors of these two domains. MethOds: 228 colorectal can-
cer survivors diagnosed October 2007–September 2009 nominated an informal carer. 
Carers were posted a questionnaire which included questions on socio-demographic 
characteristics, relationship with the care recipient, the caregiver reaction assess-
ment (CRA) scale and the SF-12v2. Multivariate linear regression was used to assess 
whether five CRA domains (family support, finances, schedule and health, esteem) 
predicted carer mental or physical health, controlling for age and other confound-
ers. Results: 153 carers (82% female) completed the questionnaire (response rate = 
68%). Carers’ mean physical component score (PCS) was 48.56 (SD= 10.38) and mean 
mental component score (MCS) was 49.22 (SD= 9.7). The most negatively affected 
CRA domain was disrupted schedule (mean= 3.0), followed by financial problems 
(mean= 2.4), health problems (mean= 2.3) and lack of family support (mean= 2.0). 
Multiple regression analysis showed health burden was the strongest predictor (β = 
-.54, p < .001) of carer PCS, followed by having a comorbid condition (β = -.34, p < .001), 
age (β = -.33, p < .001) and schedule burden (β = .25, p = .008). MCS was significantly 
predicated by financial problems (β = -.20, p = .02), age (β = -.16, p = .05) and esteem (β 
= -.16, p = .05). cOnclusiOns: Our results demonstrate the need to recognise the dif-
ferent aspects of the impact of caring on caregivers (i.e. physical and mental), and that 
different domains of subjective caregiver burden impact differently on each of these.
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The majority of patients with Non-Small Cell Lung Cancer (NSCLC) are diagnosed 
with advanced disease (Stage IV). The site of the metastasis as well as the underly-
ing disease influences the outcome and the patient’s quality of life. Objectives: 
To evaluate the impact of brain metastases compared with other metastatic sites 
on health-related quality of life (EQ-5D) and physician-perceived life expectancy 
in stage IV NSCLC patients. MethOds: Data were drawn from the Adelphi NSCLC 
Disease-Specific Programme (DSP®), a cross-sectional survey of 120 pulmonologists 
and oncologists and their NSCLC patients conducted between July and September 
2010 in France and Germany. Each physician completed detailed record forms on 
10 advanced patients being actively treated for NSCLC. Patients were invited to 
complete an equivalent patient self-completion questionnaire (PSC) which included 
the EQ-5D. Analysis was conducted on patients with only one metastatic site, either 
brain, contralateral lung, adrenal gland, bone or liver. Mann-Whitney tests were 
used to assess the differences between metastatic sites. Results: 498 patients 
with one metastatic site were identified of whom 325 (65%) completed a PSC. The 
higher the EQ-5D score the better the health state, EQ-5D was significantly lower 
for patients with brain metastases (mean 0.52, n= 29) compared with contralateral 
lung metastases (0.69, n= 111, p= 0.0196); adrenal glands (0.83, n= 43, p= 0.0001) and 
liver (0.71, n= 46, p= 0.0191). No significant difference was observed between brain 
and bone metastases (0.53, n= 92, p= 0.8219). Estimated life expectancy was signifi-
cantly shorter for brain metastases (25.3 weeks) compared with contralateral lung 
(50.5 weeks), bone (49.4 weeks), adrenal glands (48.7 weeks) and liver (44.9 weeks) 
(all p< 0.01). cOnclusiOns: The development of brain metastases in patients with 
advanced NSCLC is associated with a significant reduction in quality of life and 
estimated life expectancy compared with other metastatic sites.
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Objectives: Men with mCRPC are at risk of experiencing SREs, defined as patho-
logic bone fracture (“fracture”), spinal cord compression (“compression”), and the 
need for radiotherapy or surgery to bone (“radiotherapy/surgery”). We examined the 
patient and clinical relevance of SREs for HRQoL in men with mCRPC. MethOds: 
We analysed data from patients experiencing any type of SRE (n= 587; irrespective of 
treatment) in PREVAIL - a phase 3 trial of enzalutamide (n= 872) vs. placebo (n= 845) 
in asymptomatic/mildly symptomatic chemo-naïve mCRPC patients. For patients 
with multiple SREs, only the first event was included. HRQoL was assessed using 
the FACT-P and EQ-5D tools. Impact of first SRE on HRQoL was evaluated as follows: 
especially in comparative and longitudinal studies is recommended in order to 
enhance use of BQ in clinical decision making around BR modalities.
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Objectives: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing 
malignant tumors. So far there is no data on the patient preferences/priorities 
regarding the therapy of NET. This empirical study aimed at the elicitation of patient 
priorities in the drug treatment of NET. MethOds: Qualitative patient interviews 
(N= 9) were conducted. To elicit patient’s perspective regarding various treatment 
aspects of NET a self-administered questionnaire using Analytic Hierarchy Process 
(AHP) was developed. The data collection was carried out using paper question-
naires supported by an item response system in a group discussion. To evaluate 
the patient-relevant outcomes, the eigenvector method was applied. Results: 
N= 24 patients, experts and relatives participated in the AHP survey. In the AHP all 
respondents had clear priorities for all considered attributes. The attribute “overall 
survival” was the most significant feature of a drug therapy for all respondents. As 
in the qualitative interviews, “efficacy attributes” dominated the side effects in the 
AHP as well. The evaluation of all participants thus showed the attributes “overall 
survival” (Wglobal: 0.418), “progression free survival” (Wglobal: 0.172) and “response 
to treatment” (Wglobal: 0.161) to be most relevant. “Occurrence of abdominal pain” 
(Wglobal: 0.051) was ranked last, with “tiredness/fatigue” and “risk of a hypoglyce-
mia” (Wglobal: 0.034) on a shared seventh place. cOnclusiOns: The results thus 
provide evidence about how much influence a treatment capacity has on therapeu-
tic decision. Using the AHP major aspects of drug therapy from the perspective of 
those affected were captured, and positive and negative therapeutic properties could 
be related against each other. Based on the assessment of the patient’s perspective 
further investigation must elicit patient preferences for NET drug therapy. In the 
context of a discrete choice experiment or another choice -based method of prefer-
ence measurement, the results obtained here can be validated and the therapeutic 
features weighted according to their preferability.
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Objectives: Despite the availability of a wide number of treatments for relapsed/
refractory (r/r) chronic lymphocytic leukemia (CLL) and r/r mantle cell lymphoma 
(MCL), no standard of care has emerged. There are no studies evaluating preferences 
for treatment outcomes for r/r CLL and r/r MCL. This study was designed to elicit 
preferences for r/r MCL and r/r CLL treatment outcomes among patients, the general 
public and physicians experienced in treating CLL/MCL in Germany. MethOds: 
Interviews (90 minutes) in German of 6 CLL/6 MCL hematologists, 6 r/r CLL and 5 r/r 
MCL patients were conducted (total 23 interviews). Participants were asked to state 
their most important treatment outcomes. Transcripts were translated to English 
and analyzed by counting the number of times each outcome was mentioned. 
We present here results of patient and physician preferences. Results:  r/r CLL 
patients mention overall survival (OS; 5 counts), mode of treatment administration 
(4), quality of life (QOL) aspects (4) and progression free survival (PFS) disease control 
(4). A tolerable side effect (SE) profile/controlling disease symptoms was mentioned 
by 3 patients. Other treatment outcomes were infections, nausea (2 each), fatigue, 
weight loss, pain, fever, polyneuropathy and long treatment intervals (1 each). CLL 
physicians mentioned OS (4), QOL (4) and PFS (4). r/r MCL patients mentioned effi-
cacy benefits such as cure (4) and OS (2), PFS (1); various QOL aspects (5) and a 
tolerable SE profile/controlling disease (3). Other treatment outcomes were long-
term organ damage (2), hair loss, nausea and night sweat (1 each). MCL physicians 
mentioned OS (6), QOL (5) and a tolerable SE profile (4). cOnclusiOns: Extending 
life, disease control, maintaining QOL and avoiding SE are important r/r MCL/CLL 
treatment outcomes to German patients and physicians.
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Objectives: Lung cancer is a major cause of cancer-related deaths and thus rep-
resents a global health problem. To date, decisions on which treatment to use are 
often driven by health care professionals’ opinions. The perspective of patients 
with metastatic non-small cell lung cancer (NSCLC) on the importance of different 
treatment criteria and the ranking of these decision criteria are rarely taken into 
consideration. Aim of the study is the evaluation of patients’ preferences for differ-
ent treatment characteristics of NSCLC patients. MethOds: The literature review 
and 10 qualitative interviews revealed seven patient-relevant treatment attributes. A 
Discrete-Choice Experiment (DCE) was used to rank the patient-relevant treatment 
characteristics. The DCE was conducted using a fractional factorial design (Ngene) 
and the statistical data analysis used random effect logit and GLLAMM latent 
class models for subgroup identification. Results: In total N= 211 patients with 
metastatic NSCLC participated in the computer-assisted personal interviews. The 
estimation revealed a clear dominance for “progression-free survival” (coef.: 1.087) 
and “tumor-associated symptoms (cough, shortness of breath and pain)” (coef.: 
1.090), followed by the side effects: “nausea and vomiting” (coef.: 0.605), “rash” (coef.: 
0.432), “diarrhea” (coef.: 0.427) and “tiredness and fatigue” (coef.: 0.423). The “mode 
